During the past decade, Hematology Oncology, P.C. conducted 3 clinical trials. In the 10-year time frame, 3 clinical trials started and 11 clinical trials were completed, i.e. on average, 366.7% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 3 clinical trials were completed. i.e. 150% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Hematology Oncology, P.C." #1 sponsor was "Genentech, Inc." with 3 trials, followed by "Bristol-Myers Squibb" with 2 trials sponsored, "Celgene" with 2 trials sponsored, "Incyte Corporation" with 2 trials sponsored and "Morphotek" with 2 trials sponsored. Other sponsors include 17 different institutions and companies that sponsored additional 24 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Hematology Oncology, P.C." #1 collaborator was "AstraZeneca" with 1 trials as a collaborator, "Bristol-Myers Squibb" with 1 trials as a collaborator, "Eisai Europe Ltd. (United Kingdom)" with 1 trials as a collaborator, "Eli Lilly and Company" with 1 trials as a collaborator and "Johnson & Johnson Pharmaceutical Research & Development, L.L.C." with 1 trials as a collaborator. Other collaborators include -1 different institutions and companies that were collaborators in the rest 9 trials.

According to Clinical.Site data, the most researched conditions in "Hematology Oncology, P.C." are "Breast Cancer" (4 trials), "Melanoma" (3 trials), "Multiple Myeloma" (3 trials), "Lung Cancer" (2 trials) and "Myelofibrosis" (2 trials). Many other conditions were trialed in "Hematology Oncology, P.C." in a lesser frequency.

Most popular intervention types in "Hematology Oncology, P.C." are "Drug" (30 trials), "Other" (2 trials) and "Biological" (1 trials). Other intervention types were less common.

The name of intervention was led by "Paclitaxel" (4 trials), "Placebo" (4 trials), "Gemcitabine" (3 trials), "placebo" (3 trials) and "Capecitabine" (2 trials). Other intervention names were less common.

The vast majority of trials in "Hematology Oncology, P.C." are 26 trials for "All" genders and 7 trials for "Female" genders.

Currently, there are NaN active trials in "Hematology Oncology, P.C.". undefined are not yet recruiting, 1 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 24 completed trials in Hematology Oncology, P.C., undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Hematology Oncology, P.C., 2 "Phase 1" clinical trials were conducted, 11 "Phase 2" clinical trials and 17 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 0 trials that are defined as “Not Applicable".